Targeting liver myofibroblasts: A novel approach in anti-fibrogenic therapy

Hepatology International

Volumn 2, Issue 4, 2008, Pages 405-415

  Douglass, Angela ^a,b,c   Wallace, Karen ^a   Koruth, Matthew ^c   Barelle, Caroline ^b   Porter, Andrew J ^c   Wright, Matthew C ^c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b PFIZER INC   (United States)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

C1 3; Fibrosis; Gliotoxin; Hepatic stellate cell; Kupffer cell; Matrix metalloproteinase 13

Indexed keywords

ACETYLCYSTEINE; ADENOVIRUS VECTOR; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; CAMOSTAT MESILATE; DELTA9(11) TETRAHYDROCANNABINOL; DEXAMETHASONE; FARGLITAZAR; GLIOTOXIN; GLUCOCORTICOID; HALOFUGINONE; IRBESARTAN; LOSARTAN; METITEPINE MALEATE; NALTREXONE; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIRFENIDONE; POLAPREZINC; PROSTAGLANDIN SYNTHASE INHIBITOR; QUERCETIN; RESVERATROL; RIFAMPICIN; RIMONABANT; SALAZOSULFAPYRIDINE; SPIPERONE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; WARFARIN;

ANTIGEN BINDING; APOPTOSIS; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG CONJUGATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; HEPATITIS; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER NECROSIS; LIVER TRANSPLANTATION; MYOFIBROBLAST; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHAGE DISPLAY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; VIRAL GENE THERAPY;

EID: 57149083868     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-008-9093-y     Document Type: Review

References (88)

1. Wallace K, Burt AD, Wright MC. Liver fibrosis. Biochem J 2008;411:1-18. doi: 10.1042/BJ20071570.
2. Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: The principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci USA 1985;82:8681-8685. doi: 10.1073/pnas.82.24.8681.
3. Beaussier M, Wendum D, Schiffer E, Dumont S, Rey C, Lienhart A, et al. Prominent contribution of portal mesenchymal cells to liver fibrosis in ischemic and obstructive cholestatic injuries. Lab Invest 2007;87:292-303. doi: 10.1038/labinvest.3700513.
4. Baba S, Fujii H, Hirose T, Yasuchika K, Azuma H, Hoppo T, et al. Commitment of bone marrow cells to hepatic stellate cells in mouse. J Hepatol 2004;40:255-260. doi: 10.1016/j.jhep. 2003.10.012.
5. Russo FP, Alison MR, Bigger BW, Amofah E, Florou A, Amin F, et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 2006;130:1807-1821. doi: 10.1053/j.gastro.2006.01.036.
6. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H, et al. Fibroblasts derived from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007;282:23337-23347. doi: 10.1074/ jbc.M700194200.
7. Rygiel KA, Robertson H, Marshall HL, Pekalski M, Zhao L, Booth TA, et al. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab Invest 2008;88:112-123. doi: 10.1038/labinvest.3700704.
8. Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, et al. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther 2005;315:58-68. doi: 10.1124/jpet.105.085597.
9. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998;102:538-549. doi: 10.1172/JCI1018.
10. Pahl HL, Krauss B, Schulze-Osthoff K, Decker T, Traenckner EB, Vogt M, et al. The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB. J Exp Med 1996;183:1829-1840. doi: 10.1084/jem.183.4.1829.
11. Wright MC, Issa R, Smart DE, Trim N, Murray GI, Primrose JN, et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001;121:685-698. doi: 10.1053/gast.2001.27188.
12. Orr JG, Leel V, Cameron GA, Marek CJ, Haughton EL, Elrick LJ, et al. Mechanism of action of the antifibrogenic compound gliotoxin in rat liver cells. Hepatology 2004;40:232-242. doi: 10.1002/hep. 20254.
13. Beljaars L, Weert B, Geerts A, Meijer DK, Poelstra K. The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue. Biochem Pharmacol 2003;66:1307-1317. doi: 10.1016/S0006-2952(03)00445-3.
14. Beljaars L, Molema G, Schuppan D, Geerts A, De Bleser PJ, Weert B, et al. Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor. J Biol Chem 2000;275:12743-12751. doi: 10.1074/ jbc.275.17.12743.
15. Beljaars L, Molema G, Weert B, Bonnema H, Olinga P, Groothuis GM, et al. Albumin modified with mannose 6-phosphate: A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells. Hepatology 1999;29:1486-1493. doi: 10.1002/hep. 510290526.
16. Elrick LJ, Leel V, Blaylock MG, Duncan L, Drever MR, Strachan G, et al. Generation of a monoclonal human single chain antibody fragment to hepatic stellate cells - a potential mechanism for targeting liver anti-fibrotic therapeutics. J Hepatol 2005;42:888-896. doi: 10.1016/ j.jhep. 2005.01.028.
17. Cassiman D, van Pelt J, De Vos R, Van Lommel F, Desmet V, Yap SH, et al. Synaptophysin: A novel marker for human and rat hepatic stellate cells. Am J Pathol 1999;155:1831-1839.
18. McMahon HT, Bolshakov VY, Janz R, Hammer RE, Siegelbaum SA, Südhof TC. Synaptophysin, a major synaptic vesicle protein, is not essential for neurotransmitter release. Proc Natl Acad Sci USA 1996;93:4760-4764. doi: 10.1073/pnas.93.10.4760.
19. Clackson T, Hoogenboom HR, Griffiths AD, Winter G. Making antibody fragments using phage display libraries. Nature 1991;352:624-628. doi: 10.1038/352624a0.
20. Brissette R, Goldstein NI. The use of phage display peptide libraries for basic and translational research. Methods Mol Biol 2007;383:203-213.
21. Douglass A, Wallace K, Parr R, Park J, Durward E, Broadbent I, et al. Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury. J Hepatol 2008;49:88-98.
22. Elsharkawy AM, Wright MC, Hay RT, Arthur MJ, Hughes T, Bahr MJ, et al. Persistent activation of nuclear factor-kappaB in cultured rat hepatic stellate cells involves the induction of potentially novel Rel-like factors and prolonged changes in the expression of IkappaB family proteins. Hepatology 1999;30:761-769. doi: 10.1002/hep. 510300327.
23. Hagens WI, Olinga P, Meijer DK, Groothuis GM, Beljaars L, Poelstra K. Gliotoxin non-selectively induces apoptosis in fibrotic and normal livers. Liver Int 2006;26:232-239. doi: 10.1111/j.1478-3231.2005.01212.x.
24. Anselmi K, Stolz DB, Nalesnik M, Watkins SC, Kamath R, Gandhi CR. Gliotoxin causes apoptosis and necrosis of rat Kupffer cells in vitro and in vivo in the absence of oxidative stress: Exacerbation by caspase and serine protease inhibition. J Hepatol 2007;47:103-113. doi: 10.1016/ j.jhep. 2007.02.024.
25. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005;115:56-65.
26. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 2004;127:1704-1713. doi: 10.1053/j.gastro.2004.08.052.
27. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology 2006;43:S113-S120. doi: 10.1002/hep. 21046.
28. Fowell AJ, Iredale JP. Emerging therapies for liver fibrosis. Dig Dis 2006;24:174-183. doi: 10.1159/000090320.
29. Cortez-Pinto H, Camilo ME. Non-alcoholic fatty liver disease/ non-alcoholic steatohepatitis (NAFLD/NASH): Diagnosis and clinical course. Best Pract Res Clin Gastroenterol 2004;18:1089-1104.
30. World Health Organisation. http://www.who.int/mediacentre/factsheets/ fs164/en/. Accessed Oct 2000.
31. Kim KY, Rhim T, Choi I, Kim SS. N-acetylcysteine induces cell cycle arrest in hepatic stellate cells through its reducing activity. J Biol Chem 2001;276:40591-40598. doi: 10.1074/jbc.M100975200.
32. Kawada N, Seki S, Inoue M, Kuroki T. Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells. Hepatology 1998;27:1265-1274. doi: 10.1002/hep. 510270512.
33. Ke Z, Zhou F, Wang L, Chen S, Liu F, Fan X, et al. Down-regulation of Wnt signaling could promote bone marrow-derived mesenchymal stem cells to differentiate into hepatocytes. Biochem Biophys Res Commun 2008;367:342-348.
34. Kordes C, Sawitza I, Häussinger D. Canonical Wnt signaling maintains the quiescent stage of hepatic stellate cells. Biochem Biophys Res Commun 2008;367:116-123. doi: 10.1016/j.bbrc.2007.12.085.
35. Cheng JH, She H, Han YP, Wang J, Xiong S, Asahina K, et al. Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2008;294:G39-G49. doi: 10.1152/ ajpgi.00263.2007.
36. Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997;113:1069-1073. doi: 10.1053/ gast.1997.v113.pm9322499.
37. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:2485-2490. doi: 10.1111/ j.1572-0241.2003.08699.x.
38. Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003;112:1383-1394.
39. Ishibashi H, Komori A, Shimoda S, Gershwin ME. Guidelines for therapy of autoimmune liver disease. Semin Liver Dis 2007;27:214-226. doi: 10.1055/ s-2007-979472.
40. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003;38:S38-S53. doi: 10.1016/S0168-8278(02)00429-4.
41. Bolkenius U, Hahn D, Gressner AM, Breitkopf K, Dooley S, Wickert L. Glucocorticoids decrease the bioavailability of TGF-beta which leads to a reduced TGF-beta signaling in hepatic stellate cells. Biochem Biophys Res Commun 2004;325:1264-1270. doi: 10.1016/j.bbrc.2004.10.164.
42. Melgert BN, Olinga P, Van Der Laan JM, Weert B, Cho J, Schuppan D, et al. Targeting dexamethasone to Kupffer cells: Effects on liver inflammation and fibrosis in rats. Hepatology 2001;34:719-728. doi: 10.1053/jhep. 2001.27805.
43. Yamamoto H, Kondo M, Nakamori S, Nagano H, Wakasa K, Sugita Y, et al. JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis. Gastroenterology 2003;125:556-571. doi: 10.1016/S0016-5085(03)00904-1.
44. Yu J, Wu CW, Chu ES, Hui AY, Cheng AS, Go MY, et al. Elucidation of the role of COX-2 in liver fibrogenesis using transgenic mice. Biochem Biophys Res Commun 2008;372:571-577.
45. Oakley F, Meso M, Iredale JP, Green K, Marek CJ, Zhou X, et al. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology 2005;128:108-120. doi: 10.1053/j.gastro.2004.10.003.
46. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002;122:1924-1940. doi: 10.1053/gast.2002.33666.
47. Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacaldi S, Batignani G, et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000;119:466-478. doi: 10.1053/gast.2000.9365.
48. Lin J, Chen A. Activation of peroxisome proliferator-activated receptor-gamma by curcumin blocks the signaling pathways for PDGF and EGF in hepatic stellate cells. Lab Invest 2008;88:529-540. doi: 10.1038/ labinvest.2008.20.
49. Kliewer SA, Willson TM. Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J Lipid Res 2002;43:359-364.
50. Marek CJ, Tucker SJ, Konstantinou DK, Elrick LJ, Haefner D, Sigalas C, et al. Pregnenolone-16alpha-carbonitrile inhibits rodent liver fibrogenesis via PXR (pregnane X receptor)-dependent and PXR-independent mechanisms. Biochem J 2005;387:601-608. doi: 10.1042/BJ20041598.
51. Haughton EL, Tucker SJ, Marek CJ, Durward E, Leel V, Bascal Z, et al. Pregnane X receptor activators inhibit human hepatic stellate cell transdifferentiation in vitro. Gastroenterology 2006;131:194-209. doi: 10.1053/j.gastro.2006.04.012.
52. Podesta A, Lopez P, Terg R, Villamil F, Flores D, Mastai R, et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci 1991;36:216-220. doi: 10.1007/BF01300759.
53. Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: A meta-analysis of prospective randomized-controlled trials. Liver Int 2006;26:943-948. doi: 10.1111/ j.1478-3231.2006.01326.x.
54. Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, et al. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem 2001;276:39411-39418. doi: 10.1074/jbc.M106340200.
55. Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999;29:644-647. doi: 10.1002/hep. 510290301.
56. Yoshiji H, Kuriyama S, Fukui H. Blockade of renin-angiotensin system in antifibrotic therapy. J Gastroenterol Hepatol 2007;22:S93-S95. doi: 10.1111/j.1440-1746.2006.04663.x.
57. Wei HS, Lu HM, Li DG, Zhan YT, Wang ZR, Huang X, et al. The regulatory role of AT 1 receptor on activated HSCs in hepatic fibrogenesis: Effects of RAS inhibitors on hepatic fibrosis induced by CCl 4. World J Gastroenterol 2000;6:824-828.
58. Sookoian S, Fernández MA, Castaño G. Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: A pilot study. World J Gastroenterol 2005;11:7560-7563.
59. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001;34:745-750.
60. Peterson TC. Pentoxifylline prevents fibrosis in an animal model and inhibits platelet-derived growth factor-driven proliferation of fibroblasts. Hepatology 1993;17:486-493.
61. Desmoulière A, Xu G, Costa AM, Yousef IM, Gabbiani G, Tuchweber B. Effect of pentoxifylline on early proliferation and phenotypic modulation of fibrogenic cells in two rat models of liver fibrosis and on cultured hepatic stellate cells. J Hepatol 1999;30:621-631. doi: 10.1016/S0168-8278(99)80192-5.
62. Nicholson CD, Challiss RA, Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 1991;12:19-27. doi: 10.1016/0165-6147(91)90484-A.
63. Lee KS, Cottam HB, Houglum K, Wasson DB, Carson D, Chojkier M. Pentoxifylline blocks hepatic stellate cell activation independently of phosphodiesterase inhibitory activity. Am J Physiol 1997;273:G1094-G1100.
64. Liu P, Liu CH, Wang HN, Hu YY, Liu C. Effect of salvianolic acid B on collagen production and mitogen-activated protein kinase activity in rat hepatic stellate cells. Acta Pharmacol Sin 2002;23:733-738.
65. Luk JM, Wang X, Liu P, Wong KF, Chan KL, Tong Y, et al. Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation. Liver Int 2007;27:879-890. doi: 10.1111/j.1478-3231.2007.01527.x.
66. Liu P, Hu YY, Liu C, Zhu DY, Xue HM, Xu ZQ, et al. Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2002;8:679-685.
67. Di Sario A, Bendia E, Svegliati Baroni G, Ridolfi F, Casini A, Ceni E, et al. Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol 2002;37:584-591. doi: 10.1016/ S0168-8278(02)00245-3.
68. Pines M, Knopov V, Genina O, Lavelin I, Nagler A. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. J Hepatol 1997;27:391-398. doi: 10.1016/S0168-8278(97)80186-9.
69. Popov Y, Patsenker E, Bauer M, Niedobitek E, Schulze-Krebs A, Schuppan D. Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J Biol Chem 2006;281:15090-15098. doi: 10.1074/jbc.M600030200.
70. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Li L, et al. CB1 cannabinoid receptor antagonism: A new strategy for the treatment of liver fibrosis. Nat Med 2006;12:671-676. doi: 10.1038/ nm1421.
71. Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005;128:742-755. doi: 10.1053/j.gastro.2004.12.050.
72. Hézode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005;42:63-71. doi: 10.1002/hep. 20733.
73. Ebrahimkhani MR, Kiani S, Oakley F, Kendall T, Shariftabrizi A, Tavangar SM, et al. Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats. Gut 2006;55:1606-1616. doi: 10.1136/ gut.2005.076778.
74. Ruddell RG, Oakley F, Hussain Z, Yeung I, Bryan-Lluka LJ, Ramm GA, et al. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am J Pathol 2006;169:861-876. doi: 10.2353/ ajpath.2006.050767.
75. Anan A, Baskin-Bey ES, Bronk SF, Werneburg NW, Shah VH, Gores GJ. Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology 2006;43:335-344. doi: 10.1002/hep. 21036.
76. Novo E, Marra F, Zamara E, Valfrè di Bonzo L, Monitillo L, Cannito S, et al. Overexpression of Bcl-2 by activated human hepatic stellate cells: Resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut 2006;55:1174-1182. doi: 10.1136/ gut.2005.082701.
77. Buck M, Chojkier M. A ribosomal S-6 kinase-mediated signal to C/EBP-beta is critical for the development of liver fibrosis. PLoS ONE. 2007;2:e1372. doi: 10.1371/journal.pone.0001372.
78. George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: A potential new therapy for hepatic fibrosis. Proc Natl Acad Sci USA 1999;96:12719-12724. doi: 10.1073/pnas.96.22.12719.
79. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-129. doi: 10.1038/ng1001-117.
80. Okuno M, Akita K, Moriwaki H, Kawada N, Ikeda K, Kaneda K, et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology 2001;120:1784-1800. doi: 10.1053/gast.2001.24832.
81. Gnainsky Y, Kushnirsky Z, Bilu G, Hagai Y, Genina O, Volpin H, et al. Gene expression during chemically induced liver fibrosis: Effect of halofuginone on TGF-beta signaling. Cell Tissue Res 2007;328:153-166. doi: 10.1007/s00441-006-0330-1.
82. Sugino H, Kumagai N, Watanabe S, Toda K, Takeuchi O, Tsunematsu S, et al. Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2008; In press.
83. Brocks B, Kraft S, Zahn S, Noll S, Pan C, Schauer M, et al. Generation and optimization of human antagonistic antibodies against TIMP-1 as potential therapeutic agents in fibrotic diseases. Hum Antibodies 2006;15:115-124.
84. Salgado S, Garcia J, Vera J, Siller F, Bueno M, Miranda A, et al. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol Ther 2000;2:545-551. doi: 10.1006/mthe.2000.0210.
85. Ohayon O, Mawasi N, Pevzner A, Tryvitz A, Gildor T, Pines M, et al. Halofuginone upregulates the expression of heparinase in thioacetamide-induced liver fibrosis in rats. Lab Invest 2008;88:627-633.
86. Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003;125:1796-1807. doi: 10.1053/ j.gastro.2003.08.029.
87. Potter JJ, Womack L, Mezey E, Anania FA. Transdifferentiation of rat hepatic stellate cells results in leptin expression. Biochem Biophys Res Commun 1998;244:178-182. doi: 10.1006/bbrc.1997.8193.
88. Ikejima K, Honda H, Yoshikawa M, Hirose M, Kitamura T, Takei Y, et al. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 2001;34:288-297. doi: 10.1053/jhep. 2001.26518.